Moberg Pharma AB (publ)
MOB.ST
Stockholm Stock Exchange9.49
SEK
+0.15
- -
Moberg Pharma AB (publ)
MOB.ST
(Stockholm Stock Exchange)
Recent
price
9.49
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Moberg Pharma AB (publ) (MOB.ST) develops, manufactures, and commercializes proprietary topical pharmaceutical products focused on dermatological treatments, primarily for onychomycosis (nail fungus). The company's core product is MOB-015, a terbinafine-based cutaneous solution approved in 13 European countries and marketed as Terclara, an over-the-counter medicine that has achieved market leadership in Sweden with a 47% value share and in Norway with a 37% value share as of the third quarter of 2025; MOB-015 leverages patented formulation technology to deliver high concentrations of the antifungal agent through the nail, demonstrating 76% fungal cure rates in Phase 3 trials involving over 800 patients. Moberg Pharma operates in the specialty pharmaceuticals segment, targeting patients with mild to moderate nail fungus in consumer healthcare channels such as pharmacies, with geographic focus on Europe (including launches in Sweden since spring 2024 and Norway since February 2025), Canada, Israel, and plans for further expansion. Founded in 2006 and headquartered in Bromma, Sweden, the company was formerly known as Moberg Derma AB (publ) until its name change in May 2013. In November 2025, Moberg Pharma entered an exclusive license agreement with Karo Healthcare for MOB-015/Terclara in 19 European markets, including all major EU countries and the UK, under the Lamisil brand; Karo Healthcare assumes responsibility for marketing, distribution, and sales, while Moberg Pharma supplies product and receives royalties, marking a strategic shift toward scalable European growth without building local sales organizations. Earlier in 2025, the company raised SEK 336 million through a targeted rights issue (TO 2) and directed share issue to strengthen its balance sheet ahead of commercialization; additional partnerships include Cipher Pharmaceuticals for Canada, Allderma for Scandinavia, and Padagis for Israel. These developments support Moberg Pharma's goal to establish MOB-015 as the global market leader in nail fungus treatment, with patent protection through 2032 in key markets including the US, EU, Japan, Canada, and China.